The investigation focuses on RDY investor losses tied to Dr. Reddy’s FY27 margin guidance after the Company disclosed a ₹2.4 billion provision connected to out-of-spec semaglutide batches.

RDY shareholders saw Dr. Reddy’s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a ₹2.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi & Korsinsky is investigating potential securities law violations involving Dr. Reddy’s forward-looking profitability statements. (212) 363-7500 | www.zlk.com

Submit your RDY loss information.

On May 12, 2026, Chief Executive Officer Erez Israeli stated, “We remain in the neighbourhood of a 20% EBITDA margin and we expect the margins to improve and be above 50% in FY ‘27.”

The investigation focuses on the Company’s margin outlook and cost commentary surrounding semaglutide. Dr. Reddy’s later disclosed a ₹2.4 billion provision for out-of-spec semaglutide batches, and on the July 9, 2026 update call, Israeli stated, “nothing has changed besides this event.”

If RDY losses affected your account, send your loss details now. You may also call (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the RDY Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Dr. Reddy’s Laboratories made potentially misleading statements regarding FY27 EBITDA margin expectations, spending levels, and semaglutide-related financial impact before shares fell approximately 9%.

Q: Who is eligible to participate in the RDY investigation? A: Investors who purchased RDY stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did RDY stock drop? A: RDY shares fell approximately 9% after Dr. Reddy’s disclosed Q1 FY27 results that included a ₹2.4 billion provision tied to out-of-spec semaglutide batches.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor a court may appoint to represent affected investors. Lead plaintiffs are typically investors with the largest documented losses. Providing loss information during the investigation phase preserves that option.

Q: What if I already sold my RDY shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought RDY and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. Most affected investors do not appear in court.

Attorney Advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260728610600/en/